Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03425591
Other study ID # CR107363
Secondary ID 54179060CAN4001
Status Completed
Phase
First received
Last updated
Start date May 11, 2016
Est. completion date August 11, 2022

Study information

Verified date October 2022
Source Janssen-Cilag Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy for chronic lymphocytic leukemia (CLL) and mantle-cell lymphoma (MCL).


Recruitment information / eligibility

Status Completed
Enrollment 508
Est. completion date August 11, 2022
Est. primary completion date August 11, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Has a confirmed diagnosis of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle-cell lymphoma (MCL), and is initiating ibrutinib therapy or has initiated ibrutinib therapy on or after 21 November 2014 (date of ibrutinib commercialization) for: 1. treatment of CLL/SLL in participants who have received at least 1 prior therapy; or 2. treatment in first line CLL/SLL participants in the presence of deletion (del) 17p or TP53 mutation in participants unsuitable for chemo-immunotherapy; or 3. treatment of participants with relapsed or refractory MCL - Not currently participating in another investigational study, clinical study, or any expanded access program at study entry - Has not participated in the ibrutinib Autorisation Temporaire d'Utilisation (ATU) program - Participant must sign a written informed consent form (ICF) allowing data collection and source data verification Exclusion Criteria: - Currently participating in another investigational study, clinical study, or any expanded access program at study entry - Participated in the ibrutinib Autorisation Temporaire d'Utilisation (ATU) program

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ibrutinib
Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib in routine clinical practice settings will be observed for 5 years.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Janssen-Cilag Ltd.

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progressive-Free Survival (PFS) PFS in Chronic Lymphocytic Leukemia (CLL) and Mantle-Cell Lymphoma (MCL) participants will be determined. PFS is defined as the time from start of ibrutinib therapy to Progressive Disease (PD) or death from any cause. PD is defined as any new lesions or increase by greater than or equal to (>=) 50 percent (%) of previously involved sites from nadir. Approximately up to 5 years
Secondary Overall Response Rate (ORR) ORR observed in CLL and MCL participants will be reported. ORR is defined as the proportion of participants with at least an objective response (that is, complete response or partial response, or partial response with lymphocytosis for CLL participants) as assessed by the participating physician. Approximately up to 5 years
Secondary Time to First Response Time to First Response in CLL and MCL participants will be reported. Time to first response is defined as the time from start of ibrutinib therapy until first objective response. Approximately up to 5 years
Secondary Time to Best Response Time to best response in CLL and MCL participants will be reported. Time to best response is defined as the time from start of ibrutinib therapy until best objective response. Approximately up to 5 years
Secondary Duration of Response Duration of response in CLL and MCL participants will be reported. Duration of response is defined as the time from start of ibrutinib therapy until PD or death resulting from progression. PD is defined as any new lesions or increase by >=50% of previously involved sites from nadir. Approximately up to 5 years
Secondary Overall survival (OS) Overall survival in CLL and MCL participants will be reported. Overall survival will be measured from start of ibrutinib therapy to the date of death (all-cause mortality); and from diagnosis to the date of death. Approximately up to 5 years
Secondary Duration of Ibrutinib Therapy Duration of ibrutinib therapy in CLL and MCL participants will be reported. Approximately up to 5 years
Secondary Duration of a Treatment-Free Period Duration of treatment-free period in CLL and MCL participants will be reported. Every 6 months (Approximately up to 5 years)
Secondary Duration of the First Non-Ibrutinib Subsequent Therapy Period Duration of the first non-ibrutinib subsequent therapy period in CLL and MCL participants will be reported. Approximately up to 5 years
Secondary Participants' Daily Dose Daily dose of ibrutinib taken by CLL and MCL participants will be analyzed. Approximately up to 5 years
Secondary Number of Participants Who Require Dose Modifications Number of CLL and MCL participants requiring dose modifications in the ibrutinib therapy will be reported. Approximately up to 5 years
Secondary Number of Medications Added Number of medications added in the CLL and MCL treatment will be reported. Approximately up to 5 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03204188 - Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Phase 2
Terminated NCT00768339 - A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas Phase 1/Phase 2
Completed NCT03289182 - An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)
Terminated NCT05244070 - A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Phase 1
Completed NCT03720561 - A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting
Completed NCT02666898 - Phase II Trial GA101 Inbrutinib B CLL Phase 2
Completed NCT00738829 - Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL Phase 1/Phase 2
Completed NCT03301207 - A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy Phase 1
Completed NCT04290923 - Determination of Blood Tumor Cells
Completed NCT04204057 - Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Phase 2
Recruiting NCT03331198 - Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Phase 1/Phase 2
Completed NCT00545714 - A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL) Phase 2
Completed NCT02639910 - Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi Phase 2
Completed NCT00220311 - A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Phase 4
Active, not recruiting NCT04540796 - A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Phase 1
Recruiting NCT05650723 - Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab Phase 2
Recruiting NCT06299540 - Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia
Recruiting NCT02782351 - Humanized CAR-T Therapy for Treatment of B Cell Malignancy Phase 1/Phase 2
Completed NCT00206726 - Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL) Phase 2